Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:physicist
|
| gptkbp:approves |
gptkb:European_Union
gptkb:United_States |
| gptkbp:brand |
Glucobay
Precose |
| gptkbp:chemicalFormula |
C25H43NO18
|
| gptkbp:clinicalTrials |
Phase IV
Phase III |
| gptkbp:contraindication |
Breastfeeding
Pregnancy Inflammatory bowel disease Severe renal impairment |
| gptkbp:developedBy |
gptkb:Bayer_AG
|
| gptkbp:dosageForm |
Tablets
100 mg 50 mg 25 mg |
| gptkbp:drugInterdiction |
Absorption is minimal
Delays carbohydrate digestion Excreted in feces Metabolized by intestinal bacteria Reduces postprandial blood glucose levels |
| gptkbp:healthcare |
Support from healthcare providers
Education on side effects May require dietary changes Regular monitoring of blood glucose levels |
| https://www.w3.org/2000/01/rdf-schema#label |
Acarbose
|
| gptkbp:interactsWith |
gptkb:Metformin
Insulin Sulfonylureas |
| gptkbp:isATypeOf |
56180-94-0
|
| gptkbp:issuedBy |
Oral tablet
|
| gptkbp:lastProduced |
1990
|
| gptkbp:marketedAs |
gptkb:Australia
gptkb:Brazil gptkb:Canada gptkb:India gptkb:Japan |
| gptkbp:operates_in |
A10BF01
|
| gptkbp:researchAreas |
Cardiovascular health
Metabolic syndrome Diabetes treatment Obesity management Gastrointestinal health |
| gptkbp:safetyFeatures |
Generally well tolerated
Monitor liver function Long-term use is safe |
| gptkbp:sideEffect |
Diarrhea
Flatulence Gastrointestinal discomfort |
| gptkbp:triggerType |
Inhibits carbohydrate absorption
|
| gptkbp:usedFor |
Type 2 diabetes management
|